PIQ-PHARMA is launching a new medication Profitus®

PIQ-PHARMA LLC announces the introduction of the medication Profitus® into civilian circulation in the form of an oral solution (6 mg/ml) available in 100 ml bottles.

Profitus® is the first domestic drug based on levodropropizine, designed for the effective treatment of non-productive cough in adults and children over 2 years old.

Profitus® contains levodropropizine, which exerts an antitussive effect at the level of the respiratory tract, and also has additional anti-inflammatory and antihistaminic effects. Thus, the medication targets key components of the mechanism behind dry cough in upper respiratory infections, reducing both the frequency and intensity of coughing fits, as well as the number of nighttime awakenings. This contributes to improving the patient`s quality of life and accelerates the recovery process.

The active ingredient in the Profitus® medication, levodropropizine, is included in the Clinical Guidelines for the treatment of acute respiratory viral infections (ARVI) in adults, as well as for acute and chronic bronchitis, and in the Temporary Guidelines for the prevention and treatment of coronavirus infection.